Boehringer settles Pradaxa claims in the US for $650 million.

Boehringer Ingelheim announced that the company has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding Pradaxa(dabigatran etexilate). The settlement enables Boehringer Ingelheim to focus solely on its mission of improving patients' lives and allows the company to avoid the distraction and uncertainty of lengthy litigation. The settlement was closed at 650 million US Dollar (appr. 470 million €). It comes after a reaffirmation from the FDA of the positive benefit-risk profile of Pradaxa, when it published the results of a Medicare study of more than 134,000 patients.